Colorado Springs runs 3.5 points above Colorado on obesity, Appendix P excludes weight-loss drugs, two local clinics publish cash prices, and specialist waits run weeks to months.
28.4% of Colorado Springs adults have obesity (CDC PLACES 2025 release, BRFSS 2023, crude prevalence) 1, virtually identical to El Paso County's own 28.3% 2 and 3.5 points above Colorado's 24.9% 3. The gradient here is city-and-county versus state, not city versus county.
In a city of 487,887 inside a metro of 777,099, with a median household income of $84,818 and 4.9% uninsured 45, the constraint is not income or insurance status. It is that Colorado Medicaid excludes the indication and the local cash market starts at $148 and runs to $600.
Health First Colorado categorically excludes the classic anorexiant drug class from its pharmacy benefit: Appendix P, Prior Authorization Criteria, effective 07/01/2026 and revised 07/24/2026, lists Qsymia, Contrave, Saxenda (liraglutide), Xenical, Adipex-P, Lomaira, Belviq, and phentermine under the heading that medications prescribed for use for weight loss are not a covered benefit, verified verbatim against the primary PDF 8.
Neither Wegovy nor Zepbound appears on that anorexiant list, but that is narrower than it sounds. The companion Preferred Drug List effective 07/01/2026 shows both are prior-authorization-approvable only for indications that are not weight loss: Wegovy for adults with established cardiovascular disease plus obesity or overweight to reduce cardiovascular risk, not for weight loss alone and not layered onto a type 2 diabetes indication, and Zepbound for adults with moderate-to-severe obstructive sleep apnea plus BMI 30 or more who have already failed CPAP 9. For weight loss alone, with no CVD or OSA diagnosis on file, Colorado Medicaid covers no GLP-1, leaving El Paso County's Medicaid-enrolled population with cash-pay or a telehealth subscription.
Weight Loss Champion at 855 Garden of the Gods Rd STE A publishes 503A compounded semaglutide at $148 for the first month at 0.25mg only, then $197/month ongoing up to 2.5mg/week, and compounded tirzepatide tiered by dose at $250/month for 2-3mg, $325/month for 3.1-8.25mg, and $397/month for 8.26-16.5mg 10.
All In Family Medicine at 7610 North Union Blvd Suite 140 publishes a range rather than a flat price: cash-pay compounded GLP-1s at $250 to $600 per month, cash-pay brand-name GLP-1s at $1,200 per month, and with insurance, medication co-pays of $25 to $200 per month 11. A third local clinic, Colorado Slim, is confirmed to operate here with no published price, quoting only by call 15.
Astra's price is national and flat: $68/month semaglutide and $118/month tirzepatide on 12-month plans, $816 and $1,416 annually, the same in Colorado Springs as everywhere else.
Healthgrades lists 25 endocrinologists within 10 miles of Colorado Springs, checked 2026-08-28, for a metro of roughly 777,000, a thin bench relative to population 12. Local news reporting from KRDO in September 2024 put most of Colorado Springs at a 6 or 7 on Colorado's own physician-shortage severity scale, where 1 is least shortage and Denver and Grand Junction sit at 1, citing 4-6 month waits for new primary-care patients and a documented 7-month wait for a neurology appointment as illustrative examples 13; a separate Colorado Springs top-doctors directory checked 2026-08-28 cites 6-12 week new-patient waits for specialists including endocrinology 14. These are illustrative local signals, not a rigorous wait-time survey.
The federal picture is split. HRSA carries no Designated full-county geographic Primary Care HPSA for El Paso County, and the one broader geographic designation on file, LI Colorado Springs, is listed Proposed For Withdrawal as of Feb 2026, but two Designated primary-care shortage areas persist underneath it: a Low-Income Population HPSA (score 12, designated population 44,237, provider ratio 3,738:1) and a facility HPSA at Peak Vista Community Health Centers, the area's main FQHC network (score 18, designated population 125,769). Mental health is the sharper, county-wide gap: Diversus Health's Mental Health Care Catchment Area is a Designated Geographic HPSA (score 9, ratio 30,697:1) covering a designated population of 756,846, effectively the whole county, with Peak Vista separately carrying a Designated FQHC Mental Health HPSA (score 23, population 125,769) 67.
So general-population primary care in Colorado Springs proper isn't federally shortage-designated, but the low-income, safety-net, and mental-health slices of the county clearly are, and patients with an obesity or metabolic diagnosis face a real multi-week-to-multi-month wait locally. That wait is the practical case for telehealth prescribing here. See the Colorado GLP-1 overview for statewide context.
Astra treats patients in Colorado through state-licensed physicians.
Not for weight loss alone. Health First Colorado's Prior Authorization manual (Appendix P, effective 07/01/2026) places weight-loss drugs in a non-covered "Anorexiants" category, and neither Wegovy nor Zepbound is on that list — but the program's Preferred Drug List only approves those two names for narrow, non-weight-loss reasons: Wegovy for members with existing cardiovascular disease, Zepbound for moderate-to-severe sleep apnea after failing CPAP. If your reason for treatment is weight loss and you don't carry one of those diagnoses, Colorado Medicaid will not cover it, which is why El Paso County residents seeking GLP-1s for weight loss typically end up paying cash or using a telehealth subscription.
For most people, yes. Astra charges $68/mo for semaglutide and $118/mo for tirzepatide on 12-month plans ($816 and $1,416 a year) — the same nationwide, including Colorado Springs. Locally, Weight Loss Champion's compounded semaglutide runs $197/mo after an introductory month (compounded tirzepatide up to $397/mo at the highest dose tier), and All In Family Medicine lists compounded GLP-1s at $250-$600/mo cash-pay, or $1,200/mo for brand-name product. Against those published local prices, Astra runs roughly 50-90% lower depending on dose and provider — though some Colorado Springs clinics don't publish a price at all, so not every local option is directly comparable.
28.4% of Colorado Springs adults have obesity, per CDC PLACES crude prevalence data built from 2023 BRFSS survey responses. That's almost identical to El Paso County's own county-wide rate of 28.3%, and 3.5 percentage points above Colorado's statewide rate of 24.9%.
There's no single authoritative wait-time survey for the city, but the available signals point to a real, multi-week-to-multi-month wait. Healthgrades lists only 25 endocrinologists within 10 miles of Colorado Springs, serving a metro of roughly 777,000 people. Local news reporting (KRDO, September 2024) placed most of the city at a "6" or "7" on Colorado's own physician-shortage severity scale (Denver and Grand Junction sit at "1") and cited 4-6 month waits for new primary-care patients; a separate local directory of top-rated doctors cites 6-12 week waits for specialist appointments, including endocrinology.
Some do, some don't. Weight Loss Champion and All In Family Medicine both publish detailed GLP-1 pricing on their websites (last checked August 28, 2026). Other local weight-loss providers — Colorado Slim among them — list GLP-1 programs on their sites but don't publish a price at all, so you'd need to call for a quote.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.